Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schoonenboom, N. S.M.
Right arrow Articles by Scheltens, Ph.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schoonenboom, N. S.M.
Right arrow Articles by Scheltens, Ph.
Related Collections
Right arrow History of Neurology
Right arrow Alzheimer's disease
NEUROLOGY 2004;62:1580-1584
© 2004 American Academy of Neurology

Amyloid ß(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease

N. S.M. Schoonenboom, MD, Y. A.L. Pijnenburg, MD, C. Mulder, MSc, S. M. Rosso, MD, E. -J. Van Elk, MSc, G. J. Van Kamp, PhD, J. C. Van Swieten, MD PhD and Ph. Scheltens, MD PhD

From the Alzheimer Center (Drs. Schoonenboom, Pijnenburg, and Scheltens), Department of Neurology, and Department of Clinical Chemistry (Drs. Schoonenboom and Van Kamp, C. Mulder and E.-J. Van Elk), VU University Medical Center, Amsterdam, and Department of Neurology (Drs. Rosso and Van Swieten), Erasmus Medical Center, Rotterdam, the Netherlands.

Address correspondence and reprint requests to Dr. N.S.M. Schoonenboom, Alzheimer Center, Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands; e-mail: niki.schoonenboom{at}vumc.nl

Objective: To determine the diagnostic value of CSF amyloid ß(1–42) (Aß42), CSF total tau, and CSF tau phosphorylated at threonine-181 (Ptau-181) in early-onset Alzheimer disease (EAD) vs frontotemporal lobar degeneration (FTLD).

Methods: Levels of Aß42, total tau, and Ptau-181 in CSF were measured using commercially available ELISA in 47 EAD patients, 28 FTLD patients, and 21 nondemented control subjects.

Results: CSF Aß42 was significantly lower and CSF total tau and CSF Ptau-181 significantly higher in EAD patients than FTLD patients and control subjects. There was an increase in diagnostic accuracy for CSF Ptau-181 vs CSF total tau (p = 0.067). Combining low CSF Aß42 and high CSF Ptau-181 allowed EAD patients to be distinguished from FTLD patients with a sensitivity of 72% and a specificity of 93%. Logistic regression analysis with CSF Aß42 and CSF Ptau-181 as independent continuous variables resulted in correct classification of 46 of 47 (98%) EAD patients and 23 of 28 (82%) FTLD patients. The diagnostic accuracy for EAD was independent of gender, disease duration, and disease severity.

Conclusion: The combination of CSF Aß42 and CSF Ptau-181 may help in differentiating EAD from FTLD.

Received July 22, 2003. Accepted in final form January 9, 2004.




This article has been cited by other articles:


Home page
 NeurologyHome page
F. H. Bouwman, W. M. van der Flier, N.S.M. Schoonenboom, E. J. van Elk, A. Kok, F. Rijmen, M. A. Blankenstein, and P. Scheltens
Longitudinal changes of CSF biomarkers in memory clinic patients
Neurology, September 4, 2007; 69(10): 1006 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 Cereb CortexHome page
C. Stam, B. Jones, G Nolte, M Breakspear, and P. Scheltens
Small-World Networks and Functional Connectivity in Alzheimer's Disease
Cereb Cortex, January 1, 2007; 17(1): 92 - 99.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. M. van der Flier, S.N.M. Schoonenboom, Y. A.L. Pijnenburg, N. C. Fox, and P. Scheltens
The effect of APOE genotype on clinical phenotype in Alzheimer disease
Neurology, August 8, 2006; 67(3): 526 - 527.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. H. Bouwman, W. M. van der Flier, N. S.M. Schoonenboom, E. J. van Elk, A. Kok, P. Scheltens, and M. A. Blankenstein
Usefulness of Longitudinal Measurements of {beta}-Amyloid1-42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders.
Clin. Chem., August 1, 2006; 52(8): 1604 - 1606.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
D. Galimberti, N. Schoonenboom, P. Scheltens, C. Fenoglio, F. Bouwman, E. Venturelli, I. Guidi, M. A. Blankenstein, N. Bresolin, and E. Scarpini
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.
Arch Neurol, April 1, 2006; 63(4): 538 - 543.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
Y A L Pijnenburg, S N M Schoonenboom, F Barkhof, D L Knol, C Mulder, G J Van Kamp, J C Van Swieten, and P Scheltens
CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging
J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 246 - 248.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. S.M. Schoonenboom, C. Mulder, H. Vanderstichele, Y. A.L. Pijnenburg, G. J. Van Kamp, P. Scheltens, P. D. Mehta, and M. A. Blankenstein
Differences and Similarities between Two Frequently Used Assays for Amyloid {beta} 42 in Cerebrospinal Fluid
Clin. Chem., June 1, 2005; 51(6): 1057 - 1060.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. S.M. Schoonenboom, C. Mulder, H. Vanderstichele, E.-J. Van Elk, A. Kok, G. J. Van Kamp, P. Scheltens, and M. A. Blankenstein
Effects of Processing and Storage Conditions on Amyloid {beta} (1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice
Clin. Chem., January 1, 2005; 51(1): 189 - 195.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.